Applied Molecular Transport (NASDAQ:AMTI – Get Rating) released its results on Monday. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analyst consensus estimates of ($0.75) by ($0.35), MarketWatch Earnings reports.
AMTI shares opened at $4.37 on Tuesday. The company’s 50-day moving average is $6.00 and its two-hundred-day moving average is $11.36. Applied Molecular Transport has a 12 month minimum of $3.63 and a 12 month maximum of $52.71. The company has a market capitalization of $168.92 million, a PE ratio of -1.64 and a beta of 1.93.
In other Applied Molecular Transport news, Director Aaron Vandevender purchased 4,112 shares of Applied Molecular Transport in a trade on Monday, February 28. The shares were purchased at an average price of $6.51 per share, for a total transaction of $26,769.12. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, accessible via the SEC’s website. Company insiders own 25.40% of the company’s shares.
A number of institutional investors have recently bought and sold shares of AMTI. Millennium Management LLC increased its stake in Applied Molecular Transport by 371.4% during the fourth quarter. Millennium Management LLC now owns 556,993 shares of the company worth $7,787,000 after purchasing an additional 438,829 shares last quarter. Morgan Stanley increased its stake in Applied Molecular Transport by 1,110.9% in the third quarter. Morgan Stanley now owns 212,484 shares of the company worth $5,497,000 after acquiring an additional 194,936 shares last quarter. Renaissance Technologies LLC increased its holdings in Applied Molecular Transport by 434.2% during the 4th quarter. Renaissance Technologies LLC now owns 173,600 shares of the company valued at $2,427,000 after acquiring an additional 141,100 shares during the period. Bank of America Corp DE increased its stake in Applied Molecular Transport shares by 1,173.0% in the fourth quarter. Bank of America Corp DE now owns 116,993 shares of the company valued at $1,636,000 after purchasing an additional 107,803 shares during the period. Finally, BlackRock Inc. increased its stake in Applied Molecular Transport shares by 3.4% in the fourth quarter. BlackRock Inc. now owns 1,939,444 shares of the company worth $27,115,000 after acquiring an additional 64,034 shares in the last quarter. Hedge funds and other institutional investors hold 71.34% of the company’s shares.
About Applied Molecular Transport (Get a rating)
Applied Molecular Transport Inc, a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic and other diseases. The Company’s lead product candidate is AMT-101, an oral selective gastrointestinal (GI) fusion of rhIL-10 that is in a Phase II clinical trial for the treatment of ulcerative colitis and associated inflammatory indications.
Featured Articles
Get news and reviews for Applied Molecular Transport Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Applied Molecular Transport and related companies with MarketBeat.com’s free daily email newsletter.
Comments are closed.